Fluvoxamine vs Placebo and Time to Recovery in Outpatients With Mild to Moderate COVID-19-Reply

JAMA. 2023 May 16;329(19):1702-1703. doi: 10.1001/jama.2023.5064.
No abstract available

Publication types

  • Comment

MeSH terms

  • Antiviral Agents* / therapeutic use
  • COVID-19 Drug Treatment*
  • COVID-19* / therapy
  • Double-Blind Method
  • Fluvoxamine* / therapeutic use
  • Humans
  • Recovery of Function
  • Time Factors

Substances

  • Fluvoxamine
  • Antiviral Agents